Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)

1 Nov 1999

Abstract excerpt

In view of presumed non-pathogenicity, tumor suppressive properties, and site-specific integration of the viral genome the human parvovirus, adeno-associated virus (AAV) has gained great interest as a gene transduction vector. Data on the seroprevalence of antibodies to AAV vary between reports, probably due to the different serological methods used. In order to understand better the immune response to AAV during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to Parvovirus B19 Infection Studies
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10502275
DOI: 10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)PMID 10502275Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated VirusesSemantic proximity Read ↗

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Semantic proximity Read ↗

Challenges in Humoral Immune Response to Adeno-Associated Viruses DeterminationSemantic proximity Read ↗

Diverse IgG subclass responses to adeno‐associated virus infection and vector administrationSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive PatientsSemantic proximity Read ↗

Adeno-associated virus infection and its impact in human health: an overviewSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsSemantic proximity Read ↗

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and AdolescentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.